TY - JOUR AU - Andre, Thierry AU - Falcone, Alfredo AU - Shparyk, Yaroslav AU - Moiseenko, Fedor AU - Polo-Marques, Eduardo AU - Csoszi, Tibor AU - Campos-Bragagnoli, Arinilda AU - Liposits, Gábor AU - Chmielowska, Ewa AU - Aubel, Paul AU - Martin, Lourdes AU - Fougeray, Ronan AU - Amellal, Nadia AU - Saunders, Mark P. TI - Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study JF - LANCET GASTROENTEROLOGY AND HEPATOLOGY J2 - LANCET GASTROENT HEPATOL VL - 8 PY - 2023 IS - 2 SP - 133 EP - 144 PG - 12 SN - 2468-1253 DO - 10.1016/S2468-1253(22)00334-X UR - https://m2.mtmt.hu/api/publication/34318749 ID - 34318749 AB - Background Trifluridine-tipiracil plus bevacizumab has shown efficacy in previous phase 2 studies including patients with unresectable metastatic colorectal cancer. We aimed to investigate first-line trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer ineligible for intensive treatment.Methods In this open-label, randomised, phase 3 study, we enrolled patients aged 18 years and older with histologically confirmed metastatic colorectal cancer, ineligible for full-dose doublet or triplet chemotherapy and curative resection across 25 countries and regions. Participants were randomly allocated (1:1) to trifluridine-tipiracil plus bevacizumab or capecitabine plus bevacizumab until disease progression or unacceptable toxicity using an interactive web response system, stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1 vs 2), primary tumour location (right vs left colon), and the main reason for not being a candidate for intensive therapy (clinical condition vs non-clinical condition). The primary endpoint was investigator-assessed progression-free survival, defined as the time from randomisation to radiological progression or death from any cause, in the intention-to-treat population. Safety was assessed in all patients having taken at least one dose of the study drug. The trial is ongoing, findings presented here are those of the primary analysis of progression-free survival, conducted after 629 events had occurred. This study is registered with ClinicalTrials.gov, NCT03869892.Findings Between March 21, 2019, and Sept 14, 2020, 856 patients (54% male, 46% female) were randomly assigned to trifluridine-tipiracil plus bevacizumab (n=426) or capecitabine plus bevacizumab (n=430). After a median follow-up of 16 center dot 6 months (95% CI 16 center dot 5-17 center dot 1), the hazard ratio for progression-free survival for trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab was 0 center dot 87 (0 center dot 75-1 center dot 02; p=0 center dot 0464; protocol-defined significance level of p=0 center dot 021 not met). Investigator-assessed median progression-free survival was 9 center dot 4 months (95% CI 9 center dot 1-10 center dot 9) with trifluridine-tipiracil plus bevacizumab versus 9 center dot 3 months (8 center dot 9-9 center dot 8) with capecitabine plus bevacizumab. The most common grade 3 and higher treatment-emergent adverse events were neutropenia (220 [52%] of 423 patients in the trifluridine-tipiracil plus bevacizumab group vs six [1%] of 427 in the capecitabine plus bevacizumab group), decreased neutrophil count (78 [18%] vs four [<1%]), anaemia (60 [14%] vs 16 [4%]), and hand-foot syndrome (none vs 61 [15%]). Nine deaths (five in the trifluridine-tipiracil plus bevacizumab group and four in the capecitabine plus bevacizumab group) were treatment related.Interpretation First-line trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab in this population. As expected, the safety profile differed between the two treatments, but there were no new safety concerns. Trifluridine-tipiracil plus bevacizumab represents a feasible alternative to capecitabine plus bevacizumab in this population.Copyright (c) 2022 Elsevier Ltd. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Baxter, Mark A. AU - Marinho, Joana AU - Soto-Perez-de-Celis, Enrique AU - Rodriquenz, Maria Grazia AU - Arora, Sukeshi Patel AU - Lok, Wendy Chan Wing AU - Shih, Yung-Yu AU - Liposits, Gábor AU - O'Hanlon, Shane AU - Petty, Russell D. TI - Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric Oncology JF - JOURNAL OF GERIATRIC ONCOLOGY J2 - J GERIATR ONCOL VL - 13 PY - 2022 IS - 1 SP - 7 EP - 19 PG - 13 SN - 1879-4068 DO - 10.1016/j.jgo.2021.09.006 UR - https://m2.mtmt.hu/api/publication/33314218 ID - 33314218 AB - Gastroesophageal adenocarcinoma is a disease of older adults with very poor survival rates. Its incidence has risen dramatically across the world in recent decades. Current treatment approaches for older adults are based largely on extrapolated evidence from clinical trials conducted in younger and fitter participants than those more commonly encountered in clinical practice. Understanding how to apply available evidence to our patients in the clinic setting is essential given the high morbidity of both curative and palliative treatment. This review aims to use available data to inform the management of an older adult with gastroesophageal adenocarcinoma . (c) 2021 Elsevier Ltd. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Rasmussen, Maja Lynge AU - Liposits, Gábor AU - Yogendram, Subethini AU - Jensen, Anders Bonde AU - Linnet, Søren AU - Langkjer, Sven Tyge TI - Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer JF - ACTA ONCOLOGICA J2 - ACTA ONCOL VL - 2014 PY - 2014 IS - 53 SP - 9 EP - 1275 PG - 1267 SN - 0284-186X DO - 10.3109/0284186X.2014.918277 UR - https://m2.mtmt.hu/api/publication/2591228 ID - 2591228 AB - Maja Lynge Rasmussen 1 , 2 , 1 , 1 , S Ø Ren Linnet 2 & LA - English DB - MTMT ER - TY - BOOK AU - Cselik, Zsolt AU - Hadjiev, Janaki AU - Horváth, Ákos AU - Jánváry, Zsolt Levente AU - Kovács, Árpád AU - Liposits, Gábor AU - Vallyon, Márta AU - Mangel, László AU - Antal, Gergely ED - Kovács, Árpád ED - Hadjiev, Janaki ED - Horváth, Ákos TI - Sugárterápia ET - 0 PB - Medicina Könyvkiadó CY - Budapest PY - 2014 SP - 464 SN - 9789632264530 UR - https://m2.mtmt.hu/api/publication/2565086 ID - 2565086 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Somogyiné Ezer, Éva AU - Kovács, Árpád AU - Liposits, Gábor AU - Antal, Gergely AU - Gilincsek, Lajos AU - Zádori, Péter AU - Repa, Imre TI - Indukciós kemoterápia és modern PET-CT-MR alapú 3D kemo-radioterápia szerepe a lokálisan előrehaladott fej-nyak tumoros betegek kezelésében. Prospektív klinikai vizsgálat korai tapasztalatai JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 57 PY - 2013 IS - 1. Suppl. SP - 81 EP - 81 PG - 1 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/2504062 ID - 2504062 AB - Magyar Onkológusok Társaságának 30. kongresszusa. Pécs, 2013. november 14–16. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Lynge, Maja AU - Liposits, Gábor AU - Linnet, Søren AU - Langkjer, Sven Tyge TI - Treatment with Eribulin (Halaven) in heavily pre-treated patients with metastatic breast cancer JF - BREAST J2 - BREAST VL - 22 PY - 2013 IS - Suppl. 3. SP - S43 EP - S43 SN - 0960-9776 DO - 10.1016/S0960-9776(13)70082-1 UR - https://m2.mtmt.hu/api/publication/2482295 ID - 2482295 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Árpád AU - Benkő, András AU - Liposits, Gábor AU - Vandulek, Csaba TI - Radiotherapy of distant metastases. An overview TS - An overview JF - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND PREVENTION J2 - INT J CANCER RES PREV VL - 5 PY - 2012 IS - 1-2 SP - 89 EP - 110 PG - 22 SN - 1554-1134 UR - https://m2.mtmt.hu/api/publication/2340412 ID - 2340412 AB - Cancer related morbidity and mortality are two of the most important health care problems in the modern world. In general, the number of newly diagnosed cancer patients is increasing year by year. With the development of tumor treatment modalities (new surgery techniques, modern combined chemotherapy, sophisticated 3-4D based radiotherapy, and newly developed biological-immunotherapy modalities) in most cancer types longer survival (overall, disease free, and relapsus free) can be reached. In the natural course of invasive cancers, the possibility of the presentation of distant metastases is high. Invasive cancers have the property of vascular and lymphatic invasion and tumor cells can invade into distant organs and form metastases. The most frequent localizations of distant metastases are the followings: brain, bone, liver, lung, and lymph nodes (not regional). There are several possible modalities to be used in the treatment of distant metastases: surgery, chemotherapy, interventional methods, radiotherapy, radiosurgery, etc. In this chapter we give a general overview of the modern radiotherapy of the most frequent distant metastases, especially focusing on new trends, techniques and methods, and a general view of the latest literature. © Nova Science Publishers, Inc. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Árpád AU - Antal, Gergely AU - Glavák, Csaba AU - Hadjiev, Janaki AU - Liposits, Gábor AU - Vandulek, Csaba AU - Lakosi, Ferenc AU - Colen, Rivka C. AU - Repa, Imre TI - Treatment of head-neck cancer patients using conpas techniquer. 2 years follow up results JF - RADIOTHERAPY AND ONCOLOGY J2 - RADIOTHER ONCOL VL - 103 PY - 2012 IS - Suppl. 1 SP - S455 EP - S455 SN - 0167-8140 DO - 10.1016/S0167-8140(12)71516-5 UR - https://m2.mtmt.hu/api/publication/2209285 ID - 2209285 LA - English DB - MTMT ER - TY - CHAP AU - Kovács, Árpád AU - Benkő, András AU - Liposits, Gábor AU - Vandulek, Csaba ED - Hiroto, S Watanabe TI - Radiotherapy of distant metastases. an overview TS - an overview T2 - Horizons in cancer research PB - Nova Science Publishers CY - New York, New York SN - 9781612099224 PY - 2012 SP - 89 EP - 109 PG - 21 UR - https://m2.mtmt.hu/api/publication/1986594 ID - 1986594 LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Árpád AU - Antal, Gergely AU - Glavák, Csaba AU - Hadjiev, Janaki AU - Liposits, Gábor AU - Vandulek, Csaba AU - Lakosi, Ferenc AU - Colen, Rivka R AU - Repa, Imre TI - Technical feasibility of transperineal MR-guided prostate interventions in a low field open MR system: canine study JF - RADIOTHERAPY AND ONCOLOGY J2 - RADIOTHER ONCOL VL - 103 PY - 2012 IS - Suppl. 1 SP - S460 EP - S460 SN - 0167-8140 UR - https://m2.mtmt.hu/api/publication/1629108 ID - 1629108 LA - English DB - MTMT ER -